Thioredoxin 1 delivery as new therapeutics

Advanced Drug Delivery Reviews

Volumn 61, Issue 4, 2009, Pages 303-309

  Nakamura, Hajime ^a   Hoshino, Yuma ^b   Okuyama, Hiroaki ^c   Matsuo, Yoshiyuki ^d   Yodoi, Junji ^d  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Inflammation; Oxidative stress; Protein; Redox; Thioredoxin

Indexed keywords

ACTIVE SITES; ANIMAL MODELS; ANTI-INFLAMMATORY; ANTI-INFLAMMATORY EFFECTS; APOPTOTIC; DISULFIDE EXCHANGES; DITHIOL; HUMAN BODIES; INFLAMMATION; INFLAMMATORY DISORDERS; INHIBITORY EFFECTS; LUNG DISEASE; MIGRATION INHIBITORY FACTORS; NEOVASCULARIZATION; OVER EXPRESSIONS; REDOX; REDOX ACTIVES; STRESS CONDITIONS; THIOREDOXIN;

DRUG PRODUCTS; PATHOLOGY; SULFUR COMPOUNDS;

PROTEINS;

BLEOMYCIN; CIGARETTE SMOKE; COMPLEMENT FACTOR H; DOXORUBICIN; KAINIC ACID; MACROGOL; MACROPHAGE MIGRATION INHIBITION FACTOR; RECOMBINANT HUMAN THIOREDOXIN 1; RECOMBINANT PROTEIN; THIOREDOXIN 1; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ACUTE PANCREATITIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; BRAIN INFARCTION; C57BL 6 MOUSE; CARDIOTOXICITY; CELL PROTECTION; COMPLEMENT ACTIVATION; CONTINUOUS INFUSION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; ENTERITIS; EXCITOTOXICITY; HEPATITIS; HUMAN; INFLAMMATION; INTERSTITIAL PNEUMONIA; LEUKOCYTE ADHERENCE; LUNG EMPHYSEMA; MONKEY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; RAT; REVIEW; SUBRETINAL NEOVASCULARIZATION; TRANSGENIC MOUSE; VIRUS PNEUMONIA; VOLUNTEER;

ANIMALS; CHEMOTACTIC FACTORS; COMPLEMENT INACTIVATOR PROTEINS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; NEUTROPHILS; THIOREDOXINS;

EID: 64149131454     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.01.003     Document Type: Review

References (41)

1. Holmgren A. Thioredoxin. Annu. Rev. Biochem. 54 (1985) 237-271
2. Laurent T.C., Moore E.C., and Reichard P. Enzymatic synthesis of deoxyribonucleotides IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J. Biol. Chem. 239 (1964) 3436-3444
3. Tagaya Y., Maeda Y., Mitsui A., Kondo N., Matsui H., Hamuro J., Brown N., Arai K., Yokota T., Wakasugi H., and Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; Possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J. 8 (1989) 757-764
4. Wollman E.E., d'Auriol L., Rimsky L., Shaw A., Jacquot J.P., Wingfield P., Graber P., Dessarps F., Robin P., Galibert F., et al. Cloning and expression of a cDNA for human thioredoxin. J. Biol. Chem. 263 (1988) 15506-15512
5. Nakamura H., Masutani H., and Yodoi J. Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer. Semin. Cancer Biol. 16 (2006) 444-451
6. Jeong W., Yoon H.W., Lee S.R., and Rhee S.G. Identification and characterization of TRP14, a thioredoxin-related protein of 14 kDa. New insights into the specificity of thioredoxin function. J. Biol. Chem. 279 (2004) 3142-3150
7. Miranda-Vizuete A., Sadek C.M., Jimenez A., Krause W.J., Sutovsky P., and Oko R. The mammalian testis-specific thioredoxin system. Antioxid. Redox Signal. 6 (2004) 25-40
8. Wrammert J., Kallberg E., and Leanderson T. Identification of a novel thioredoxin-related protein, PC-TRP, which is preferentially expressed in plasma cells. Eur. J. Immunol. 34 (2004) 137-146
9. Kleemann R., Kapurniotu A., Frank R.W., Gessner A., Mischke R., Flieger O., Juttner S., Brunner H., and Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J. Mol. Biol. 280 (1998) 85-102
10. Rundlofand A.K., and Arner E.S. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal. 6 (2004) 41-52
11. Kang S.W., Rhee S.G., Chang T.S., Jeong W., and Choi M.H. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol. Med. 11 (2005) 571-578
12. Fujino G., Noguchi T., Matsuzawa A., Yamauchi S., Saitoh M., Takeda K., and Ichijo H. Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1. Mol. Cell. Biol. 27 (2007) 8152-8163
13. Nakamura H., Nakamura K., and Yodoi J. Redox regulation of cellular activation. Annu. Rev. Immunol. 15 (1997) 351-369
14. Takagi Y., Mitsui A., Nishiyama A., Nozaki K., Sono H., Gon Y., Hashimoto N., and Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. U S A. 96 (1999) 4131-4136
15. Takagi Y., Hattori I., Nozaki K., Mitsui A., Ishikawa M., Hashimoto N., and Yodoi J. Excitotoxic hippocampal injury is attenuated in thioredoxin transgenic mice. J. Cereb. Blood Flow Metab. 20 (2000) 829-833
16. Shioji K., Kishimoto C., Nakamura H., Masutani H., Yuan Z., Oka S., and Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation. 106 (2002) 1403-1409
17. Nakamura H., Tamura S., Watanabe I., Iwasaki T., and Yodoi J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol. Lett. 82 (2002) 165-170
18. Hoshino T., Nakamura H., Okamoto M., Kato S., Araya S., Nomiyama K., Oizumi K., Young H.A., Aizawa H., and Yodoi J. Redox-active protein thioredoxin prevents proinflammatory cytokine-or bleomycin-induced lung injury. Am. J. Respir. Crit. Care Med. 168 (2003) 1075-1083
19. Ahsan M., Nakamura H., Tanito M., Yamada K., Utsumi H., and Yodoi J. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic. Biol. Med. 39 (2005) 1549-1559
20. Sato A., Hoshino Y., Hara T., Muro S., Nakamura H., Mishima M., and Yodoi J. Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J. Pharmacol. Exp. Ther. 325 (2008) 380-388
21. Kasuno K., Nakamura H., Ono T., Muso E., and Yodoi J. Protective roles of thioredoxin, a redox-regulating protein, in renal ischemia/reperfusion injury. Kidney Int. 64 (2003) 1273-1282
22. Okuyama H., Nakamura H., Shimahara Y., Araya S., Kawada N., Yamaoka Y., and Yodoi J. Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. Hepatology. 37 (2003) 1015-1025
23. Okuyama H., Nakamura H., Shimahara Y., Uyama N., Kwon Y.W., Kawada N., Yamaoka Y., and Yodoi J. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J. Hepatol. 42 (2005) 117-123
24. Tamaki H., Nakamura H., Nishio A., Nakase H., Ueno S., Uza N., Kido M., Inoue S., Mikami S., Asada M., Kiriya K., Kitamura H., Ohashi S., Fukui T., Kawasaki K., Matsuura M., Ishii Y., Okazaki K., Yodoi J., and Chiba T. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology. 131 (2006) 1110-1121
25. Ohashi S., Nishio A., Nakamura H., Kido M., Ueno S., Uza N., Inoue S., Kitamura H., Kiriya K., Asada M., Tamaki H., Matsuura M., Kawasaki K., Fukui T., Watanabe N., Nakase H., Yodoi J., Okazaki K., and Chiba T. Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 290 (2006) G772-781
26. Mitsui A., Hamuro J., Nakamura H., Kondo N., Hirabayashi Y., Ishizaki-Koizumi S., Hirakawa T., Inoue T., and Yodoi J. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox Signal. 4 (2002) 693-696
27. Kondo N., Ishii Y., Kwon Y.W., Tanito M., Horita H., Nishinaka Y., Nakamura H., and Yodoi J. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J. Immunol. 172 (2004) 442-448
28. Burke-Gaffney A., Callister M.E., and Nakamura H. Thioredoxin: friend or foe in human disease?. Trends Pharmacol. Sci. 26 (2005) 398-404
29. Nakamura H., Matsuda M., Furuke K., Kitaoka Y., Iwata S., Toda K., Inamoto T., Yamaoka Y., Ozawa K., and Yodoi J. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol. Lett. 42 (1994) 75-80
30. Fukuse T., Hirata T., Yokomise H., Hasegawa S., Inui K., Mitsui A., Hirakawa T., Hitomi S., Yodoi J., and Wada H. Attenuation of ischaemia reperfusion injury by human thioredoxin. Thorax. 50 (1995) 387-391
31. Okubo K., Kosaka S., Isowa N., Hirata T., Hitomi S., Yodoi J., Nakano M., and Wada H. Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung. J. Thorac. Cardiovasc. Surg. 113 (1997) 1-9
32. Bertini R., Howard O.M., Dong H.F., Oppenheim J.J., Bizzarri C., Sergi R., Caselli G., Pagliei S., Romines B., Wilshire J.A., Mengozzi M., Nakamura H., Yodoi J., Pekkari K., Gurunath R., Holmgren A., Herzenberg L.A., and Ghezzi P. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J. Exp. Med. 189 (1999) 1783-1789
33. Nakamura H., Herzenberg L.A., Bai J., Araya S., Kondo N., Nishinaka Y., and Yodoi J. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc. Natl. Acad. Sci. U S A. 98 (2001) 15143-15148
34. Ueda S., Nakamura T., Yamada A., Teratani A., Matsui N., Furukawa S., Hoshino Y., Narita M., Yodoi J., and Nakamura H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci. 79 (2006) 1170-1177
35. Nakamura T., Hoshino Y., Yamada A., Teratani A., Furukawa S., Okuyama H., Ueda S., Wada H., Yodoi J., and Nakamura H. Recombinant human thioredoxin-1 becomes oxidized in circulation and suppresses bleomycin-induced neutrophil recruitment in the rat airway. Free Radic. Res. 41 (2007) 1089-1098
36. Hara T., Kondo N., Nakamura H., Okuyama H., Mitsui A., Hoshino Y., and Yodoi J. Cell-surface thioredoxin-1: possible involvement in thiol-mediated leukocyte-endothelial cell interaction through lipid rafts. Antioxid. Redox Signal. 9 (2007) 1427-1438
37. Kondo N., Ishii Y., Kwon Y.W., Tanito M., Sakakura-Nishiyama J., Mochizuki M., Maeda M., Suzuki S., Kojima M., Kim Y.C., Son A., Nakamura H., and Yodoi J. Lipid-raft-mediated uptake of cysteine-modified thioredoxin-1 enhances cisplatin-induced apoptosis by inhibiting the endogenous thioredoxin-1. Antioxid. Redox Signal. 9 (2007) 1439-1448
38. Inomata Y., Tanihara H., Tanito M., Okuyama H., Hoshino Y., Kinumi T., Kawaji T., Kondo N., Yodoi J., and Nakamura H. Suppression of choroidal neovascularization by thioredoxin-1 via interaction with complement factor H. Invest. Ophthalmol. Vis. Sci. 49 (2008) 5118-5125
39. Kondo N., Ishii Y., Son A., Sakakura-Nishiyama J., Kwon Y.W., Tanito M., Nishinaka Y., Matsuo Y., Nakayama T., Taniguchi M., and Yodoi J. Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins. Immunol. Lett. 92 (2004) 143-147
40. Aeberli D., Leech M., and Morand E.F. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford). 45 (2006) 937-943
41. Makino Y., Okamoto K., Yoshikawa N., Aoshima M., Hirota K., Yodoi J., Umesono K., Makino I., and Tanaka H. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J. Clin. Invest. 98 (1996) 469-477